Liquid Biopsy in Diagnosis and Prognosis of High-Grade Gliomas; State-of-the-Art and Literature Review
Abstract
:1. Introduction
2. Materials and Methods
- Full articles in English
- Studies already in the “clinical phase”
- Studies regarding patients with only high-grade gliomas
- Studies regarding patients with age > 18
- Studies reporting data in terms of sensitivity and specificity.
3. Results
3.1. Biomarkers
3.1.1. miRNAs
3.1.2. ctDNA
3.1.3. Extracellular Vesicles
4. Discussion
4.1. EVs (Extracellular Vesicles)
4.2. CTCs (Circulating Tumor Cells) and ctDNA (Circulating Tumor DNA)
4.3. miRNAs
4.4. TEPs
4.5. Liquid Biopsy Limits in Clinical Uses, Diagnosis, Prognosis
4.6. The State of the Art
5. Conclusions
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Arceci, R. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Yearb. Oncol. 2009, 2009, 185–186. [Google Scholar] [CrossRef]
- Komotar, R.J.; Otten, M.L.; Moise, G.; Connolly, E.S., Jr. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review. Clin. Med. Oncol. 2008, 2, 421–422. [Google Scholar] [CrossRef] [PubMed]
- Giammalva, G.R.; Iacopino, D.G.; Azzarello, G.; Gaggiotti, C.; Graziano, F.; Gulì, C.; Pino, M.A.; Maugeri, R. End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective. Brain Sci. 2018, 8, 125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kondo, T. Molecular mechanisms involved in gliomagenesis. Brain Tumor Pathol. 2017, 34, 1–7. [Google Scholar] [CrossRef]
- Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820. [Google Scholar] [CrossRef] [Green Version]
- Llaguno, S.A.; Sun, D.; Pedraza, A.M.; Vera, E.; Wang, Z.; Burns, D.K.; Parada, L.F. Cell-of-origin susceptibility to glioblastoma formation declines with neural lineage restriction. Nat. Neurosci. 2019, 22, 545–555. [Google Scholar] [CrossRef]
- Molinaro, A.M.; Taylor, J.W.; Wiencke, J.K.; Wrensch, M.R. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol. 2019, 15, 405–417. [Google Scholar] [CrossRef]
- Sanson, M.; Hosking, F.J.; Shete, S.; Zelenika, D.; Dobbins, S.E.; Ma, Y.; Enciso-Mora, V.; Idbaih, A.; Delattre, J.-Y.; Hoang-Xuan, K.; et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum. Mol. Genet. 2011, 20, 2897–2904. [Google Scholar] [CrossRef]
- Shahzad, U.; Krumholtz, S.; Rutka, J.; Das, S. Noncoding RNAs in Glioblastoma: Emerging Biological Concepts and Potential Therapeutic Implications. Cancers 2021, 13, 1555. [Google Scholar] [CrossRef]
- Santisukwongchote, S.; Teerapakpinyo, C.; Chankate, P.; Techavichit, P.; Boongird, A.; Sathornsumetee, S.; Thammachantha, S.; Cheunsuchon, P.; Tanboon, J.; Thorner, P.S.; et al. Simplified approach for pathological diagnosis of diffuse gliomas in adult patients. Pathol. Res. Pract. 2021, 223, 153483. [Google Scholar] [CrossRef]
- Poulet, G.; Massias, J.; Taly, V. Liquid Biopsy: General Concepts. Acta Cytol. 2019, 63, 449–455. [Google Scholar] [CrossRef] [PubMed]
- Eibl, R.H.; Schneemann, M. Liquid Biopsy and Primary Brain Tumors. Cancers 2021, 13, 5429. [Google Scholar] [CrossRef] [PubMed]
- Mader, S.; Pantel, K. Liquid Biopsy: Current Status and Future Perspectives. Oncol. Res. Treat. 2017, 40, 404–408. [Google Scholar] [CrossRef] [PubMed]
- Diehl, F.; Schmidt, K.; Choti, M.A.; Romans, K.; Goodman, S.; Li, M.; Thornton, K.; Agrawal, N.; Sokoll, L.; Szabo, S.A.; et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14, 985–990. [Google Scholar] [CrossRef]
- Chen, M.; Zhao, H. Next-generation sequencing in liquid biopsy: Cancer screening and early detection. Hum. Genom. 2019, 13, 34. [Google Scholar] [CrossRef] [Green Version]
- Cainap, C.; Balacescu, O.; Cainap, S.S.; Pop, L.-A. Next Generation Sequencing Technology in Lung Cancer Diagnosis. Biology 2021, 10, 864. [Google Scholar] [CrossRef]
- Xu, X.; Yang, Y.; Li, H.; Chen, Z.; Jiang, G.; Fei, K. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing. Scand. J. Clin. Lab. Investig. 2016, 76, 386–392. [Google Scholar] [CrossRef]
- Flores-Pérez, J.A.; Oliva, F.D.L.R.; Argenes, Y.; Meneses-Garcia, A. Nutrition, Cancer and Personalized Medicine. In Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics; Springer: Cham, Switzerland, 2019; Volume 1168, pp. 157–168. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Olioso, D.; Caccese, M.; Santangelo, A.; Lippi, G.; Zagonel, V.; Cabrini, G.; Lombardi, G.; Dechecchi, M. Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study. Cancers 2021, 13, 3006. [Google Scholar] [CrossRef]
- Swellam, M.; Bakr, N.M.; El Magdoub, H.M.; Hamza, M.S.; El Arab, L.R.E. Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis. J. Mol. Neurosci. 2020, 71, 836–844. [Google Scholar] [CrossRef]
- Palande, V.; Siegal, T.; Detroja, R.; Gorohovski, A.; Glass, R.; Flueh, C.; Kanner, A.A.; Laviv, Y.; Har-Nof, S.; Levy-Barda, A.; et al. Detection of gene mutations and gene–gene fusions in circulating cell-free DNA of glioblastoma patients: An avenue for clinically relevant diagnostic analysis. Mol. Oncol. 2021. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Wang, J.; Wang, Z.; Ruan, C.; Wang, L.; Guo, H. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients. Cancer Biomark. 2019, 24, 43–49. [Google Scholar] [CrossRef] [PubMed]
- Swellam, M.; El Arab, L.E.; Al-Posttany, A.S.; Said, S.B. Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform. J. Neuro-Oncol. 2019, 144, 545–551. [Google Scholar] [CrossRef] [PubMed]
- Manda, S.V.; Kataria, Y.; Tatireddy, B.R.; Ramakrishnan, B.; Ratnam, B.G.; Lath, R.; Ranjan, A.; Ray, A. Exosomes as a biomarker platform for detecting epidermal growth factor receptor–positive high-grade gliomas. J. Neurosurg. 2018, 128, 1091–1101. [Google Scholar] [CrossRef] [Green Version]
- Figueroa, J.M.; Skog, J.; Akers, J.; Li, H.; Komotar, R.; Jensen, R.; Ringel, F.; Yang, I.; Kalkanis, S.; Thompson, R.; et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-Oncol. 2017, 19, 1494–1502. [Google Scholar] [CrossRef]
- Barone, F.; Alberio, N.; Iacopino, D.G.; Giammalva, G.R.; D’Arrigo, C.; Tagnese, W.; Graziano, F.; Cicero, S.; Maugeri, R. Brain Mapping as Helpful Tool in Brain Glioma Surgical Treatment—Toward the “Perfect Surgery”? Brain Sci. 2018, 8, 192. [Google Scholar] [CrossRef] [Green Version]
- Giammalva, G.R.; Brunasso, L.; Costanzo, R.; Paolini, F.; Umana, G.E.; Scalia, G.; Gagliardo, C.; Gerardi, R.M.; Basile, L.; Graziano, F.; et al. Brain Mapping-Aided SupraTotal Resection (SpTR) of Brain Tumors: The Role of Brain Connectivity. Front. Oncol. 2021, 11, 645854. [Google Scholar] [CrossRef]
- Gatto, L.; Franceschi, E.; Di Nunno, V.; Tosoni, A.; Lodi, R.; Brandes, A.A. Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. Oncologist 2021, 26, 865–878. [Google Scholar] [CrossRef]
- Del Bene, M.; Osti, D.; Faletti, S.; Beznousenko, G.V.; DiMeco, F.; Pelicci, G. Extracellular vesicles: The key for precision medicine in glioblastoma. Neuro-Oncology 2021, 24, 184–196. [Google Scholar] [CrossRef]
- Osti, D.; Del Bene, M.; Rappa, G.; Santos, M.; Matafora, V.; Richichi, C.; Faletti, S.; Beznoussenko, G.V.; Mironov, A.; Bachi, A.; et al. Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients. Clin. Cancer Res. 2018, 25, 266–276. [Google Scholar] [CrossRef] [Green Version]
- Yekula, A.; Yekula, A.; Muralidharan, K.; Kang, K.; Carter, B.S.; Balaj, L. Extracellular Vesicles in Glioblastoma Tumor Microenvironment. Front. Immunol. 2020, 10, 3137. [Google Scholar] [CrossRef] [PubMed]
- Bunda, S.; Zuccato, J.; Voisin, M.; Wang, J.; Nassiri, F.; Patil, V.; Mansouri, S.; Zadeh, G. Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors. Int. J. Mol. Sci. 2021, 22, 4548. [Google Scholar] [CrossRef] [PubMed]
- Akers, J.C.; Hua, W.; Li, H.; Ramakrishnan, V.; Yang, Z.; Quan, K.; Zhu, W.; Li, J.; Figueroa, J.; Hirshman, B.R.; et al. A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget 2017, 8, 68769–68779. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holdhoff, M.; Yovino, S.G.; Boadu, O.; Grossman, S.A. Blood-based biomarkers for malignant gliomas. J. Neuro-Oncol. 2013, 113, 345–352. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Yuan, F.; Qi, Y.; Liu, B.; Chen, Q. Circulating Tumor Cells for Glioma. Front. Oncol. 2021, 11, 576. [Google Scholar] [CrossRef]
- Kolostova, K.; Pospisilova, E.; Pavlickova, V.; Bartos, R.; Sames, M.; Pawlak, I.; Bobek, V. Next generation sequencing of glio-blastoma circulating tumor cells: Non-invasive solution for disease monitoring. Am. J. Transl. Res. 2021, 13, 4489–4499. [Google Scholar]
- Ali, H.; Harting, R.; de Vries, R.; Ali, M.; Wurdinger, T.; Best, M.G. Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review. Front. Oncol. 2021, 11, 5235. [Google Scholar] [CrossRef]
- Simonelli, M.; Dipasquale, A.; Orzan, F.; Lorenzi, E.; Persico, P.; Navarria, P.; Pessina, F.; Nibali, M.C.; Bello, L.; Santoro, A.; et al. Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: Close to the clinic? Crit. Rev. Oncol. 2020, 146, 102879. [Google Scholar] [CrossRef]
- Sabedot, T.S.; Malta, T.M.; Snyder, J.; Nelson, K.; Wells, M.; Decarvalho, A.C.; Mukherjee, A.; Chitale, D.A.; Mosella, M.S.; Sokolov, A.; et al. A serum-based DNA methylation assay provides accurate detection of glioma. Neuro-Oncol. 2021, 23, 1494–1508. [Google Scholar] [CrossRef]
- Śledzińska, P.; Bebyn, M.G.; Furtak, J.; Kowalewski, J.; Lewandowska, M.A. Prognostic and Predictive Biomarkers in Gliomas. Int. J. Mol. Sci. 2021, 22, 10373. [Google Scholar] [CrossRef]
- Chen, J.; Huan, W.; Zuo, H.; Zhao, L.; Huang, C.; Liu, X.; Hou, S.; Qi, J.; Shi, W. Alu methylation serves as a biomarker for non-invasive diagnosis of glioma. Oncotarget 2016, 7, 26099–26106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Birkó, Z.; Nagy, B.; Klekner, Á.; Virga, J. Novel Molecular Markers in Glioblastoma—Benefits of Liquid Biopsy. Int. J. Mol. Sci. 2020, 21, 7522. [Google Scholar] [CrossRef] [PubMed]
- Piccioni, D.E.; Achrol, A.S.; Kiedrowski, L.A.; Banks, K.; Boucher, N.; Barkhoudarian, G.; Kelly, D.F.; Juarez, T.; Lanman, R.B.; Raymond, V.M.; et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019, 8, CNS34. [Google Scholar] [CrossRef] [PubMed]
- Von Baumgarten, L.; Kumbrink, J.; Jung, A.; Reischer, A.; Flach, M.; Liebmann, S.; Metzeler, K.; Holch, J.W.; Niyazi, M.; Thon, N.; et al. Therapeutic management of neuro-oncologic patients—Potential relevance of CSF liquid biopsy. Theranostics 2020, 10, 856–866. [Google Scholar] [CrossRef]
- Seoane, J.; De Mattos-Arruda, L.; Le Rhun, E.; Bardelli, A.; Weller, M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann. Oncol. 2019, 30, 211–218. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Z.; Zhang, C.; Li, M.; Shen, Y.; Feng, S.; Liu, J.; Li, F.; Hou, L.; Chen, Z.; Jiang, J.; et al. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas. Jpn. J. Clin. Oncol. 2020, 50, 325–332. [Google Scholar] [CrossRef]
- Caruso Bavisotto, C.; Graziano, F.; Rappa, F.; Marino Gammazza, A.; Logozzi, M.; Fais, S.; Maugeri, R.; Bucchieri, F.; Conway de Macario, E.; Macario, A.J.L.; et al. Exosomal Chaperones and miRNAs in Gliomagenesis: State-of-Art and Theranostics Perspectives. Int. J. Mol. Sci. 2018, 19, 2626. [Google Scholar] [CrossRef] [Green Version]
- In ’t Veld, S.G.J.G.; Wurdinger, T. Tumor-educated platelets. Blood 2019, 133, 2359–2364. [Google Scholar] [CrossRef]
- Di Vito, C.; Navone, S.E.; Marfia, G.; Hadi, L.A.; Mancuso, M.E.; Pecci, A.; Crisà, F.M.; Berno, V.; Rampini, P.; Campanella, R.; et al. Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release. Platelets 2016, 28, 585–594. [Google Scholar] [CrossRef]
- Campanella, R.; Guarnaccia, L.; Cordiglieri, C.; Trombetta, E.; Caroli, M.; Carrabba, G.; La Verde, N.; Rampini, P.; Gaudino, C.; Costa, A.; et al. Tumor-Educated Platelets and Angiogenesis in Glioblastoma: Another Brick in the Wall for Novel Prognostic and Targetable Biomarkers, Changing the Vision from a Localized Tumor to a Systemic Pathology. Cells 2020, 9, 294. [Google Scholar] [CrossRef] [Green Version]
- Nakajima, H.; Kotani, D.; Bando, H.; Kato, T.; Oki, E.; Shinozaki, E.; Sunakawa, Y.; Yamazaki, K.; Yuki, S.; Nakamura, Y.; et al. REMARRY and PURSUIT trials: Liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. BMC Cancer 2021, 21, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Ou, S.-H.I.; Nagasaka, M.; Zhu, V.W. Liquid Biopsy to Identify Actionable Genomic Alterations. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 978–997. [Google Scholar] [CrossRef] [PubMed]
- Loupakis, F.; Sharma, S.; Derouazi, M.; Murgioni, S.; Biason, P.; Rizzato, M.D.; Rasola, C.; Renner, D.; Shchegrova, S.; Malashevich, A.K.; et al. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients with Colorectal Cancer Undergoing Resection of Metastases. JCO Precis. Oncol. 2021, 5, 1166–1177. [Google Scholar] [CrossRef] [PubMed]
- Leighl, N.B.; Page, R.D.; Raymond, V.M.; Daniel, D.B.; Divers, S.G.; Reckamp, K.L.; Villalona-Calero, M.A.; Dix, D.; Odegaard, J.I.; Lanman, R.B.; et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Clin. Cancer Res. 2019, 25, 4691–4700. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eerkes, T.; Santiago-Walker, A.A.; Loreen, M.; Lim, L.; Hernandez, J.; Raymond, C.; Henderson, S.; DiPasquo, D.; Shaffer, T.; Motely, C.; et al. Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting. Ann. Oncol. 2016, 27, vi401. [Google Scholar] [CrossRef]
- Barata, P.; Agarwal, N.; Nussenzveig, R.; Gerendash, B.; Jaeger, E.; Hatton, W.; Ledet, E.; Lewis, B.; Layton, J.; Babiker, H.; et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J. Immunother. Cancer 2020, 8, e001065. [Google Scholar] [CrossRef]
- Garcia, C.M.; Toms, S.A. The Role of Circulating MicroRNA in Glioblastoma Liquid Biopsy. World Neurosurg. 2020, 138, 425–435. [Google Scholar] [CrossRef]
- Zachariah, M.; Oliveira-Costa, J.P.; Carter, B.; Stott, S.L. Blood-Based Biomarkers for the Diagnosis and Monitoring of Gliomas. Neuro Oncol. 2020, 1, 10–13. [Google Scholar] [CrossRef] [Green Version]
Author, Year | Type of Study | Patients (n) | Biomarker | Sample | Detection Method | Role | Sensitivity | Specificity |
---|---|---|---|---|---|---|---|---|
Olioso D. et al., 2021 [20] | Prospective study | 52 GBM 5 anaplastic astrocytoma | miR-21 miR-222 miR-124-3p | serum | qRT-PCR |
|
| |
Swellam M. et al., 2021 [21] | Prospective study | 25 GBM 20 HC | miR-17-5p miR-125b miR-221 | blood | qRT-PCR |
| 50.5% 52.9% 76.5% | 100% 100% 100% |
Palande V. et al., 2021 [22] | Prospective study | 25 GBM 25 HC | cfDNA | plasma | NGS |
| 80% | 90% |
Zhang H. et al., 2019 [23] | Prospective study | 95 GBM 60 HC | miR-100 | blood | qRT-PCR |
| 77.89% | 83.33% |
Swellam M. et al., 2019 [24] | Prospective study | 20 GBM, 20 HC | miR-221 miR-222 | Serum | qRT-PCR |
| 90% 90% | 90% 85% |
Manda SV. et al., 2018 [25] | Prospective study | 96 high-grade gliomas 50 HC | EGFRvIII RNA in serum-derived EVs | Serum | PCR |
| 81.58% | 79.31% |
Figueroa JM. et al., 2017 [26] | Prospective study | 71 | wtEGFR and EGFRvIII RNA in CSF-derived EVs. | CSF | PCR |
| 61% | 98% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bonosi, L.; Ferini, G.; Giammalva, G.R.; Benigno, U.E.; Porzio, M.; Giovannini, E.A.; Musso, S.; Gerardi, R.M.; Brunasso, L.; Costanzo, R.; et al. Liquid Biopsy in Diagnosis and Prognosis of High-Grade Gliomas; State-of-the-Art and Literature Review. Life 2022, 12, 407. https://doi.org/10.3390/life12030407
Bonosi L, Ferini G, Giammalva GR, Benigno UE, Porzio M, Giovannini EA, Musso S, Gerardi RM, Brunasso L, Costanzo R, et al. Liquid Biopsy in Diagnosis and Prognosis of High-Grade Gliomas; State-of-the-Art and Literature Review. Life. 2022; 12(3):407. https://doi.org/10.3390/life12030407
Chicago/Turabian StyleBonosi, Lapo, Gianluca Ferini, Giuseppe Roberto Giammalva, Umberto Emanuele Benigno, Massimiliano Porzio, Evier Andrea Giovannini, Sofia Musso, Rosa Maria Gerardi, Lara Brunasso, Roberta Costanzo, and et al. 2022. "Liquid Biopsy in Diagnosis and Prognosis of High-Grade Gliomas; State-of-the-Art and Literature Review" Life 12, no. 3: 407. https://doi.org/10.3390/life12030407